Clinical and Microbiological End Points in the Treatment of Pneumonia | Zendy

Daniel M. Musher | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical and Microbiological End Points in the Treatment of Pneumonia

Author(s) -

Daniel M. Musher

Publication year - 2008

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/591406

Subject(s) - medicine , pneumonia , food and drug administration , intensive care medicine , antibiotics , antimicrobial , microbiology and biotechnology , pharmacology , biology

The US Food and Drug Administration is reviewing its criteria for evaluating new antibiotics for the treatment of bacterial pneumonia. Although there are descriptions of hundreds of comparative studies of various antimicrobials, there is surprisingly little scientific literature on how the evaluations should be done. This brief contribution outlines areas for further consideration as new drugs are evaluated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research